FDA Approves CellCept Combination For Heart Transplantation
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves CellCept Combination For Heart Transplantation

NUTLEY, NJ -- February 12, 1998 -- The United States Food and Drug Administration has granted marketing clearance to Hoffmann-La Roche Inc. for the expanded use of CellCept(R) (mycophenolate mofetil), to be used in combination with cyclosporine and corticosteroids for the prevention of organ rejection in patients undergoing heart transplants.

The FDA based its decision on results of a trial which showed that CellCept was safe and effective in heart transplantation. The 650-patient trial was the first prospective, double-blind, controlled study to examine the effects of immunosuppressants on acute rejection and survival in heart-transplant patients.

"Because there is a national shortage of organ donors, physicians must do everything to prevent the available organs from being rejected," said Dr. Donna Mancini, medical director of cardiac transplantation, divisions of circulatory physiology and cardiology, at Columbia Presbyterian Medical Center in New York. "CellCept offers physicians and patients a new standard of care in the field of heart transplantation by helping to ensure that those hearts that are available have a higher rate of success."

Each year, about 3,900 people in the United States are put on a waiting list for a heart transplant and only 2,000 people will receive one. Of those who receive a heart transplant, approximately 300 will experience a rejection episode.

CellCept is an immunosuppressant that was approved by the FDA in May 1995 for use in combination with cyclosporine and corticosteroids for the prevention of organ rejection in kidney-transplant patients. In kidney-transplant patients, CellCept has been shown to significantly reduce the incidence of rejection within the first six months of kidney transplantation, without any observed additional kidney or liver toxicities.

The principal adverse reactions associated with the administration of CellCept include diarrhea, leukopenia (reduction of white blood cells), sepsis and vomiting and there is evidence of a higher frequency of certain types of infections.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities